Clik here to view.
Telix Launches “Gallium Wave” Awareness Website
MELBOURNE, Australia & INDIANAPOLIS Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of a new website “Gallium Wave” (galliumwave.com), as part of the...
View ArticleClik here to view.
Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) for valemetostat, a potential first-in-class specific and potent dual inhibitor...
View ArticleClik here to view.
Celltrion Healthcare presents the first real-world data for Truxima®...
INCHEON, South Korea Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10)...
View ArticleClik here to view.
アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す
米カリフォルニア州アーバイン & アムステルダム （ビジネスワイヤ） — 乳がんの精密オンコロジー分野における世界的リーダー企業であるアジェンディアは本日、NSABP B-42試験の試料に当社の70遺伝子マンマプリント検査法を適用して、良好な解析結果が得られたと発表しました。これらの結果は2021年米国臨床腫瘍学会（ASCO）年次総会の口頭発表で報告しました。...
View ArticleClik here to view.
Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education...
MELBOURNE, Australia & INDIANAPOLIS Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of TelixU, a new educational platform focused on radiopharmaceutical...
View ArticleClik here to view.
HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate...
CAMBRIDGE, Mass. & HONG KONG & HANGZHOU, China & SHANGHAI & PARIS HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug...
View ArticleClik here to view.
Kheiron’s AI Breast Screening Solution Mia® Receives Regulatory Clearance in...
LONDON Marking a new milestone for artificial intelligence (AI) adoption in the Australian and New Zealand breast screening community, the Mia® solution, created by United Kingdom-based Kheiron...
View ArticleClik here to view.
沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台，树立高分辨质谱性能新标杆
美国马萨诸塞州米尔福德市 (美国商业资讯)– 沃特世公司（纽约证券交易所代码：WAT）隆重推出Waters SELECT SERIES MRT高分辨率质谱仪，该平台结合多反射飞行时间（MRT）质谱技术与经过改进的DESI和新型MALDI成像离子源，集高速、高分辨率和高质量精度优势于一体，助力科学家精准识别和定位样品中的单个分子，从而深入研究分子结构及其功能。...
View ArticleClik here to view.
Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials
CAMBRIDGE, Mass. & SHANGHAI Anji Pharma (“Anji”), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has...
View ArticleClik here to view.
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for...
TOKYO & NEW YORK Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the...
View ArticleClik here to view.
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510,...
SINGAPORE Prestige BioPharma Limited (PBP) specializing in the development of antibody therapeutics, announced that French National Agency for the Safety of Medicines and Health Products (L’Agence...
View ArticleClik here to view.
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq:...
View ArticleClik here to view.
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase...
DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass. Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), today announced final results from a Phase 1b/2a study on BRII-179...
View ArticleClik here to view.
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel...
BOSTON & DAEJEON, South Korea Orum Therapeutics, a biotech company pioneering the development of targeted protein degraders to treat cancer, today announced the close of a $84 million Series B...
View ArticleClik here to view.
レゴケム・バイオサイエンスとIksuda Therapeuticsが抗体薬物複合体を開発するためのライセンス契約を拡大
英ニューカッスル （ビジネスワイヤ） — 治療指数を高めた新世代の抗体薬物複合体（ADC）の開発を手掛けるIksuda Therapeuticsは本日、レゴケム・バイオサイエンス（LCB）との共同研究およびライセンス契約を拡大し、LCBの専有的ADCプラットフォーム技術を活用して、追加的なADCプログラムを追求すると発表しました。...
View ArticleClik here to view.
Kite Joint Venture – Fosun Kite – Gains the First CAR T-cell Therapy Approval...
SANTA MONICA, Calif. Kite, a Gilead Company, announced that Fosun Kite Biotechnology Co., Ltd., a joint venture between Kite and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, has received approval...
View ArticleClik here to view.
剑桥大学孵化的初创公司Lucida Medical加入GE医疗爱迪生加速器(Edison™ Accelerator)计划
英格兰剑桥 (美国商业资讯)–剑桥大学初创公司Lucida Medical今天宣布，公司已加入爱迪生加速器(Edison Accelerator)计划。该计划由GE医疗(GE Healthcare)与创新组织Wayra UK合作设计，旨在支持技术先进的早期阶段企业开发针对医疗保健行业的人工智能应用。 加入爱迪生加速器计划让Lucida Medical朝着自己的目标迈出一大步。Lucida...
View ArticleClik here to view.
ケンブリッジ大学のスピンアウト企業ルシーダ・メディカルがGEヘルスケアのエジソン・アクセラレーター・プログラムに参加
英ケンブリッジ （ビジネスワイヤ） — ケンブリッジの新興企業ルシーダ・メディカルは本日、GEヘルスケアがイノベーション組織Wayra UKと提携してデザインしたエジソン・アクセラレーター・プログラムに参加し、ヘルスケア向けAIアプリケーションの開発を手掛ける早期段階の先進技術企業を支援すると発表しました。...
View Article